Kopecka J - Search Results

1

Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma.

Mujumdar P, Kopecka J, Bua S, Supuran CT, Riganti C, Poulsen SA. Mujumdar P, et al. Among authors: kopecka j. J Med Chem. 2019 Apr 25;62(8):4174-4192. doi: 10.1021/acs.jmedchem.9b00282. Epub 2019 Apr 10. J Med Chem. 2019. PMID: 30925064 Free article.

2

iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells.

De Boo S, Kopecka J, Brusa D, Gazzano E, Matera L, Ghigo D, Bosia A, Riganti C. De Boo S, et al. Among authors: kopecka j. Mol Cancer. 2009 Nov 19;8:108. doi: 10.1186/1476-4598-8-108. Mol Cancer. 2009. PMID: 19925669 Free PMC article.

3

Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells.

Kopecka J, Campia I, Brusa D, Doublier S, Matera L, Ghigo D, Bosia A, Riganti C. Kopecka J, et al. J Cell Mol Med. 2011 Jul;15(7):1492-504. doi: 10.1111/j.1582-4934.2010.01137.x. J Cell Mol Med. 2011. PMID: 20716130 Free PMC article.

4

A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells.

Kopecka J, Campia I, Olivero P, Pescarmona G, Ghigo D, Bosia A, Riganti C. Kopecka J, et al. J Control Release. 2011 Jan 20;149(2):196-205. doi: 10.1016/j.jconrel.2010.10.003. Epub 2010 Oct 12. J Control Release. 2011. PMID: 20946921

5

Pleiotropic effects of cardioactive glycosides.

Riganti C, Campia I, Kopecka J, Gazzano E, Doublier S, Aldieri E, Bosia A, Ghigo D. Riganti C, et al. Among authors: kopecka j. Curr Med Chem. 2011;18(6):872-85. doi: 10.2174/092986711794927685. Curr Med Chem. 2011. PMID: 21182478 Review.

6

Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells.

Riganti C, Voena C, Kopecka J, Corsetto PA, Montorfano G, Enrico E, Costamagna C, Rizzo AM, Ghigo D, Bosia A. Riganti C, et al. Among authors: kopecka j. Mol Pharm. 2011 Jun 6;8(3):683-700. doi: 10.1021/mp2001389. Epub 2011 May 5. Mol Pharm. 2011. PMID: 21491921

7

Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity.

Polimeni M, Voena C, Kopecka J, Riganti C, Pescarmona G, Bosia A, Ghigo D. Polimeni M, et al. Among authors: kopecka j. Biochem J. 2011 Oct 1;439(1):141-9. doi: 10.1042/BJ20102016. Biochem J. 2011. PMID: 21679161

8

Digoxin and ouabain induce the efflux of cholesterol via liver X receptor signalling and the synthesis of ATP in cardiomyocytes.

Campia I, Sala V, Kopecka J, Leo C, Mitro N, Costamagna C, Caruso D, Pescarmona G, Crepaldi T, Ghigo D, Bosia A, Riganti C. Campia I, et al. Among authors: kopecka j. Biochem J. 2012 Oct 15;447(2):301-11. doi: 10.1042/BJ20120200. Biochem J. 2012. PMID: 22845468

9

Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance.

Riganti C, Rolando B, Kopecka J, Campia I, Chegaev K, Lazzarato L, Federico A, Fruttero R, Ghigo D. Riganti C, et al. Among authors: kopecka j. Mol Pharm. 2013 Jan 7;10(1):161-74. doi: 10.1021/mp300311b. Epub 2012 Dec 7. Mol Pharm. 2013. PMID: 23186264 Free article.

10

Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells.

Riganti C, Castella B, Kopecka J, Campia I, Coscia M, Pescarmona G, Bosia A, Ghigo D, Massaia M. Riganti C, et al. Among authors: kopecka j. PLoS One. 2013 Apr 12;8(4):e60975. doi: 10.1371/journal.pone.0060975. Print 2013. PLoS One. 2013. Retraction in: PLoS One. 2020 Dec 15;15(12):e0244194. doi: 10.1371/journal.pone.0244194. PMID: 23593363 Free PMC article. Retracted.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

168 results

Search Page